Histological improvement (dichotomous) · active EoE patients
Corticosteroids leads to higher histological improvement (dichotomous) compared with placebo (high certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
Corticosteroids showed no clear difference in endoscopic improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · inactive EoE patients
It is very uncertain whether corticosteroids changes clinical improvement (dichotomous) compared with placebo (very low certainty).
1 finding from 1 review
Clinical improvement (continuous) · inactive EoE patients
1 finding from 1 review
Vomiting ‐ intraoperative · women undergoing regional anaesthesia for caesarean section
It is very uncertain whether corticosteroids changes vomiting ‐ intraoperative compared with placebo (very low certainty).
1 finding from 1 review
Nausea · women undergoing regional anaesthesia for caesarean section
Corticosteroids probably leads to lower nausea ‐ postoperative compared with placebo (moderate certainty).
2 findings from 1 review
Vomiting ‐ postoperative · women undergoing regional anaesthesia for caesarean section
Corticosteroids may leads to lower vomiting ‐ postoperative compared with placebo (low certainty).
1 finding from 1 review
AHI · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Desaturation index (number of times per hour of sleep time that the blood's O₂ level drops by a certain proportion from baseline) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Respiratory arousal index (number of times per hour of sleep time that an increased respiratory effort without a decrease in oxygen saturation is recorded) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Nadir SpO₂ (lowest SpO₂ during sleep) · Children with obstructive sleep apnoea (aged 15 years or younger)
1 finding from 1 review
Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Early all‐cause mortality (≤ 3 months) Reported at: day 14; day 28; day 60; and in hospital · adults with acute respiratory distress syndrome
Corticosteroids showed no clear difference in early all‐cause mortality (≤ 3 months) Reported at: day 14; day 28;… compared with control (low certainty).
1 finding from 1 review
Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome
It is very uncertain whether corticosteroids changes late all‐cause mortality ( > 3 months) Reported at: 180 days compared with control (very low certainty).
1 finding from 1 review
Duration of mechanical ventilation · adults with acute respiratory distress syndrome
1 finding from 1 review
Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome
1 finding from 1 review
Adverse events Defined as leading to discontinuation of study medication; or for studies with standard care control, defined by study authors as "serious adverse events" · adults with acute respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found